563 related articles for article (PubMed ID: 31704217)
1. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
[TBL] [Abstract][Full Text] [Related]
2. Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.
Lob SH; Hoban DJ; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2018 Dec; 15():12-19. PubMed ID: 29857057
[TBL] [Abstract][Full Text] [Related]
3.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
[No Abstract] [Full Text] [Related]
4. In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2020 Jun; 21():223-228. PubMed ID: 31698105
[TBL] [Abstract][Full Text] [Related]
5. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628
[TBL] [Abstract][Full Text] [Related]
6. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
7. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
[TBL] [Abstract][Full Text] [Related]
8. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Gueny ME; Sahm DF
J Antimicrob Chemother; 2019 Aug; 74(8):2284-2288. PubMed ID: 31086960
[TBL] [Abstract][Full Text] [Related]
9.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760135
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
Karlowsky JA; Lob SH; Kazmierczak KM; Hawser SP; Magnet S; Young K; Motyl MR; Sahm DF
J Antimicrob Chemother; 2018 Jul; 73(7):1872-1879. PubMed ID: 29659861
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):274-281. PubMed ID: 32535630
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
15.
Lob SH; Hackel MA; Kazmierczak KM; Young K; Motyl MR; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320716
[TBL] [Abstract][Full Text] [Related]
16. Carbapenem-Nonsusceptible
Asempa TE; Nicolau DP; Kuti JL
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31118271
[No Abstract] [Full Text] [Related]
17. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013
[TBL] [Abstract][Full Text] [Related]
18. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
Diagn Microbiol Infect Dis; 2019 Oct; 95(2):212-215. PubMed ID: 31174995
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
